Federated Hermes, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

$52.5 Billion
Q3 2025

A detailed history of Federated Hermes, Inc. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 1,508 shares of ARWR stock, worth $57,077. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,508

Holding current value

$57,077

% of portfolio

0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 03, 2025	BUY	$14.71 - $34.49 $22,182 - $52,010	1,508 New	1,508 $52,000
Q4 2024 Feb 13, 2025	SELL	$17.7 - $26.34 $14,195 - $21,124	-802 Reduced 14.13%	4,875 $91,000
Q3 2024 Nov 13, 2024	SELL	$19.36 - $29.54 $29,504 - $45,018	-1,524 Reduced 21.16%	5,677 $109,000
Q2 2024 Aug 08, 2024	SELL	$21.87 - $28.24 $164,834 - $212,844	-7,537 Reduced 51.14%	7,201 $187,000
Q1 2024 May 14, 2024	BUY	$27.21 - $39.48 $198,850 - $288,519	7,308 Added 98.36%	14,738 $421,000
Q4 2023 Jan 31, 2024	SELL	$21.2 - $31.03 $34,407 - $50,361	-1,623 Reduced 17.93%	7,430 $227,000
Q3 2023 Nov 13, 2023	SELL	$26.2 - $36.08 $40,426 - $55,671	-1,543 Reduced 14.56%	9,053 $243,000
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $26,543 - $43,655	1,055 Added 11.06%	10,596 $377,000
Q1 2023 May 08, 2023	SELL	$23.68 - $38.51 $50,391 - $81,949	-2,128 Reduced 18.24%	9,541 $242,000
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $178,472 - $258,529	-6,374 Reduced 35.33%	11,669 $473,000
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $135,557 - $221,018	4,575 Added 33.97%	18,043 $596,000
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $262,282 - $477,657	-9,438 Reduced 41.2%	13,468 $475,000
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $146,158 - $258,119	3,689 Added 19.2%	22,906 $1.05 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $195,937 - $278,306	-3,373 Reduced 14.93%	19,217 $1.27 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $3.2 Million - $4.65 Million	-54,757 Reduced 70.79%	22,590 $1.41 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $113,050 - $164,292	1,819 Added 2.41%	77,347 $6.41 Million
Q1 2021 May 13, 2021	BUY	$61.35 - $90.47 $1.35 Million - $1.99 Million	22,018 Added 41.15%	75,528 $5.01 Million
Q4 2020 Feb 12, 2021	BUY	$43.82 - $85.37 $1.53 Million - $2.99 Million	34,971 Added 188.63%	53,510 $4.11 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $547,666 - $845,493	-16,491 Reduced 47.08%	18,539 $798,000
Q2 2020 Aug 13, 2020	SELL	$26.12 - $43.27 $4.17 Million - $6.91 Million	-159,678 Reduced 82.01%	35,030 $1.51 Million
Q1 2020 May 13, 2020	SELL	$20.56 - $63.12 $2.3 Million - $7.06 Million	-111,867 Reduced 36.49%	194,708 $5.6 Million
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $5.45 Million - $14.1 Million	193,552 Added 171.25%	306,575 $19.4 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $398,863 - $529,488	-15,189 Reduced 11.85%	113,023 $3.19 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $2.22 Million - $3.66 Million	127,157 Added 12052.8%	128,212 $3.4 Million
Q1 2019 May 10, 2019	BUY	$12.05 - $20.18 $4,350 - $7,284	361 Added 52.02%	1,055 $19,000
Q4 2018 Feb 13, 2019	SELL	$10.74 - $19.7 $1.25 Million - $2.3 Million	-116,506 Reduced 99.41%	694 $8,000
Q3 2018 Nov 13, 2018	BUY	$14.0 - $20.3 $1.25 Million - $1.81 Million	89,055 Added 316.41%	117,200 $2.25 Million
Q2 2018 Aug 10, 2018	BUY	$6.37 - $14.02 $173,302 - $381,428	27,206 Added 2897.34%	28,145 $383,000
Q1 2018 May 09, 2018	BUY	$3.72 - $7.64 $3,493 - $7,173	939 New	939 $7,000

Others Institutions Holding ARWR

# of Institutions

332

Shares Held

99.7M

Call Options Held

444K

Put Options Held

568K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $4.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History